Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 21, Issue 2, 2010, Pages 585-596

  Güntert, Andreas ^a,b   Campbell, James ^a   Saleem, Muzamil ^a,b   O'Brien, Darragh P ^a   Thompson, Andrew J ^a   Byers, Helen L ^a   Ward, Malcolm A ^a   Lovestone, Simon ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Alzheimer's disease; biomarker; disease progression; mass spectrometry; plasma gelsolin

Indexed keywords

ALPHA 1 MICROGLOBULIN; ALPHA 2 MACROGLOBULIN; AMYLOID BETA PROTEIN; ANGIOTENSINOGEN; ANTITHROMBIN III; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 12; CERULOPLASMIN; CLUSTERIN; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C8; FIBRINOGEN; FIBRONECTIN; GELSOLIN; HEMOPEXIN; INTER ALPHA TRYPSIN INHIBITOR; KININOGEN; OROSOMUCOID; PROTEIN C; SERUM AMYLOID A; UNINDEXED DRUG; VITAMIN D BINDING PROTEIN; VITRONECTIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; CEREBELLUM; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 77957345937     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100279     Document Type: Article

References (66)

1. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
2. Glenner GG, Wong CW, Quaranta V, Eanes ED (1984) The amyloid deposits in Alzheimer's disease: Their nature and pathogenesis. Appl Pathol 2, 357-369.
3. Lee VM, Trojanowski JQ (1992) The disordered neuronal cytoskeleton in Alzheimer's disease. Curr Opin Neurobiol 2, 653-656.
4. Shi M, Caudle WM, Zhang J (2009) Biomarker discovery in neurodegenerative diseases: Aproteomic approach. Neurobiol Dis 35, 157-164.
5. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ, Zhang J (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9, 293-348.
6. Choe L, D'Ascenzo M, Relkin NR, Pappin D, Ross P, Williamson B, Guertin S, Pribil P, LeeKH (2007) 8plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease. Proteomics 7, 3651-3660.
7. Dayon L,Hainard A, Licker V, TurckN,KuhnK,Hochstrasser DF, Burkhard PR, Sanchez JC (2008) Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6plex isobaric tags. Anal Chem 80, 2921-2931.
8. Hergenroeder G, Redell JB, Moore AN, Dubinsky WP, Funk RT, Crommett J, Clifton GL, Levine R, Valadka A, Dash PK (2008) Identification of serum biomarkers in braininjured adults: Potential for predicting elevated intracranial pressure. J Neurotrauma 25, 79-93.
9. Song F, Poljak A, Smythe GA, Sachdev P (2009) Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev 61, 69-80.
10. Britschgi M, WyssCoray T (2009) Blood protein signature for the early diagnosis of Alzheimer disease. Arch Neurol 66, 161-165.
11. Irizarry MC (2004) Biomarkers of Alzheimer disease in plasma. NeuroRx 1, 226-234.
12. Andreasen N, Sjogren M, Blennow K (2003) CSF markers for Alzheimer's disease: Total tau, phosphotau and Abeta42. World J Biol Psychiatry 4, 147-155.
13. Holmes C, Lovestone S (2003) Longterm cognitive and functional decline in late onset Alzheimer's disease: Therapeutic implications. Age Ageing 32, 200-204.
14. Brooks JO, 3rd, Yesavage JA (1995) Identification of fast and slow decliners in Alzheimer disease: A different approach. Alzheimer Dis Assoc Disord 9(Suppl 1), S1925.
15. Tombaugh TN, McIntyre NJ (1992) The minimental state examination: A comprehensive review. J Am Geriatr Soc 40, 922-935.
16. Weyer G, Erzigkeit H, Kanowski S, Ihl R, Hadler D (1997) Alzheimer's Disease Assessment Scale: Reliability and validity in a multicenter clinical trial. Int Psychogeriatr 9, 123-138.
17. Palermo G, Piraino P, Zucht H (2009) Performance of PLS regression coefficients in selecting variables for each response of a multivariate PLS for omicstype data. Advances and Applications in Bioinformatics and Chemistry, 57-70.
18. Eriksson L, Johansson E, KettanehWold N, Trygg J, Wikstrom C, Wold S (2006) Multivariate and Megavariate Data Analysis Basic Principles and Applications (Part I).
19. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1, 307-310.
20. Bauer DE, Haroutunian V, McCullumsmith RE, MeadorWoodruff JH(2009) Expression of four housekeeping proteins in elderly patients with schizophrenia. J Neural Transm 116, 487-491.
21. ThompsonA, Schafer J,KuhnK,Kienle S, Schwarz J, Schmidt G, Neumann T, Johnstone R, Mohammed AK, Hamon C (2003) Tandem mass tags: A novel quantification strategy for comparative analysis of complex protein mixtures byMS/MS. Anal Chem 75, 1895-1904.
22. Aggarwal K, Choe LH, Lee KH (2006) Shotgun proteomics using the iTRAQ isobaric tags. Brief Funct Genomic Proteomic 5, 112-120.
23. van Ulsen P, Kuhn K, Prinz T, Legner H, Schmid P, Baumann C, Tommassen J (2009) Identification of proteins of Neisseria meningitidis induced under ironlimiting conditions using the isobaric tandem mass tag (TMT) labeling approach. Proteomics 9, 17711781.
24. Maurya P, Meleady P, Dowling P, Clynes M (2007) Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res 27, 1247-1255.
25. Garbis SD, Tyritzis SI, Roumeliotis T, Zerefos P, Giannopoulou EG, Vlahou A, Kossida S, Diaz J, Vourekas S, Tamvakopoulos C, Pavlakis K, Sanoudou D, Constantinides CA (2008) Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using aminespecific isobaric tagging (iTRAQ)with twodimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 7, 3146-3158.
26. Matta A, DeSouza LV, Shukla NK, Gupta SD, Ralhan R, Siu KW (2008) Prognostic significance of headandneck cancer biomarkers previously discovered and identified using iTRAQlabeling and multidimensional liquid chromatographytandem mass spectrometry. J Proteome Res 7, 2078-2087.
27. Ralhan R, Desouza LV, Matta A, Chandra Tripathi S, Ghanny S, Datta Gupta S, Bahadur S, Siu KW (2008) Discovery and verification of headandneck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 7, 1162-1173.
28. LuH,Yang Y, Allister EM,Wijesekara N,WheelerMB (2008) The identification of potential factors associated with the development of type 2 diabetes: A quantitative proteomic approach. Mol Cell Proteomics 7, 1434-1451.
29. Ray S, Britschgi M, Herbert C, TakedaUchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J,Miller BL,Minthon L,Quinn JF, Rabinovici GD, RobinsonWH, SabbaghMN, So YT, Sparks DL, Taba ton M, Tinklenberg J, Yesavage JA, Tibshirani R,WyssCoray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362.
30. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S (2006) Proteomebased plasma biomarkers for Alzheimer's disease. Brain 129, 3042-3050.
31. BaranowskaBik A, Bik W, WolinskaWitort E, Martynska L, Chmielowska M, Barcikowska M, Baranowska B (2008) Plasma beta amyloid and cytokine profile in women with Alzheimer's disease. Neuro Endocrinol Lett 29, 75-79.
32. Anderson NL, Anderson NG (2002) The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 1, 845867.
33. Jacobs JM, Adkins JN, Qian WJ, Liu T, Shen Y, Camp DG, 2nd, Smith RD (2005) Utilizing human blood plasma for proteomic biomarker discovery. J Proteome Res 4, 1073-1085.
34. Gong Y, Li X, Yang B, Ying W, Li D, Zhang Y, Dai S, Cai Y, Wang J, He F, Qian X (2006) Different immunoaffinity fractionation strategies to characterize the human plasma proteome. J Proteome Res 5, 1379-1387.
35. Howard T, Chaponnier C, Yin H, Stossel T (1990) Gelsolinactin interaction and actin polymerization in human neutrophils. J Cell Biol 110, 1983-1991.
36. Kwiatkowski DJ (1999) Functions of gelsolin: Motility, signaling, apoptosis, cancer. Curr Opin Cell Biol 11, 103-108.
37. Lee WM, Galbraith RM (1992) The extracellular actinscavenger system and actin toxicity. N Engl J Med 326, 1335-1341.
38. Spinardi L, Witke W (2007) Gelsolin and diseases. Subcell Biochem 45, 55-69.
39. BuckiR, Levental I,KulakowskaA, Janmey PA(2008) Plasma gelsolin: Function, prognostic value, and potential therapeutic use. Curr Protein Pept Sci 9, 541-551.
40. Suhler E, Lin W, Yin HL, Lee WM (1997) Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med 25, 594-598.
41. Ito H, Kambe H, Kimura Y, Nakamura H, Hayashi E, Kishimoto T,Kishimoto S, Yamamoto H (1992) Depression of plasma gelsolin level during acute liver injury. Gastroenterology 102, 1686-1692.
42. Wiederin J, Rozek W, Duan F, Ciborowski P (2009) Biomarkers of HIV1 associated dementia: Proteomic investigation of sera. Proteome Sci 7, 8.
43. OsbornTM,VerdrenghM, StosselTP, TarkowskiA,Bokarewa M (2008) Decreased levels of the gelsolin plasma isoform in patientswith rheumatoid arthritis. Arthritis Res Ther 10, R117.
44. Mounzer KC, Moncure M, Smith YR, Dinubile MJ (1999) Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am J Respir Crit Care Med 160, 1673-1681.
45. Lee PS, Drager LR, Stossel TP,Moore FD, Rogers SO (2006) Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients. Ann Surg 243, 399-403.
46. Lee PS, Sampath K, Karumanchi SA, Tamez H, Bhan I, Isakova T, Gutierrez OM, Wolf M, Chang Y, Stossel TP, Thadhani R (2009) Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J Am Soc Nephrol 20, 11401148.
47. Kulakowska A, Drozdowski W, Sadzynski A, Bucki R, Janmey PA (2008) Gelsolin concentration in cerebrospinal fluid from patients with multiple sclerosis and other neurological disorders. Eur J Neurol 15, 584-588.
48. Levy E, Haltia M, FernandezMadrid I, Koivunen O, Ghiso J, Prelli F, Frangione B (1990) Mutation in gelsolin gene in Finnish hereditary amyloidosis. J Exp Med 172, 1865-1867.
49. MauryCP,Kere J, TolvanenR, de laChapelleA(1990) Finnish hereditary amyloidosis is caused by a single nucleotide substitution in the gelsolin gene. FEBS Lett 276, 7577.
50. Kiuru S, Salonen O, Haltia M (1999) Gelsolinrelated spinal and cerebral amyloid angiopathy. Ann Neurol 45, 305-311.
51. Chauhan VP, Ray I, Chauhan A,Wisniewski HM(1999) Binding of gelsolin, a secretory protein, to amyloid betaprotein. Biochem Biophys Res Commun 258, 241-246.
52. Ji L, Chauhan A, Chauhan V (2008) Cytoplasmic gelsolin in pheochromocytoma12 cells forms a complex with amyloid betaprotein. Neuroreport 19, 463-466.
53. Chauhan V, Ji L, Chauhan A (2008) Antiamyloidogenic, antioxidant and antiapoptotic role of gelsolin in Alzheimer's disease. Biogerontology 9, 381-389.
54. Ray I, Chauhan A, Wegiel J, Chauhan VP (2000) Gelsolin inhibits the fibrillization of amyloid betaprotein, and also defibrillizes its preformed fibrils. Brain Res 853, 344-351.
55. Qiao H,Koya RC, Nakagawa K, Tanaka H, Fujita H, Takimoto M, Kuzumaki N (2005) Inhibition of Alzheimer's amyloidbeta peptideinduced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin. Neurobiol Aging 26, 849-855.
56. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562.
57. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J,Mount HT,NixonRA,MerckenM, BergeronC, Fraser PE, StGeorgeHyslop P, Westaway D (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982.
58. Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K (2003) Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to betaamyloid. J Neurosci 23, 29-33.
59. HirkoAC,Meyer EM,KingMA,Hughes JA(2007) Peripheral transgene expression of plasma gelsolin reduces amyloid in transgenic mouse models of Alzheimer's disease. Mol Ther 15, 1623-1629.
60. Ji L, Chauhan A, Wegiel J, Essa MM, Chauhan V (2009) Gelsolin is proteolytically cleaved in the brains of individuals with Alzheimer's disease. J Alzheimers Dis 18, 105-111.
61. Floyd RA, Hensley K (2002) Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 23, 795-807.
62. Zhang A, Lorke DE, Lai HW, Chu X, Wu Y, Yew DT (2004) Agerelated alterations in cytochrome cmediated caspase activation in rhesus macaque monkey (Macaca mulatta) brains. Brain Res Mol Brain Res 123, 112-120.
63. Zhang A, Lorke DE, Wu SX, Yew DT (2006) Caspase3 immunoreactivity in different cortical areas of young and aging macaque (Macaca mulatta) monkeys. Neurosignals 15, 64-73.
64. Albrecht S, BourdeauM, BennettD,Mufson EJ, Bhattacharjee M, LeBlanc AC (2007) Activation of caspase6 in aging and mild cognitive impairment. Am J Pathol 170, 1200-1209. (Pubitemid 47339328)
65. Lee PS, Waxman A (2006) The importance of differentiating gelsolin isoforms. AmJ Respir Crit CareMed 173, 685; author reply 685.
66. (1998) Consensus report of theWorking Group on: Molecular and BiochemicalMarkers ofAlzheimer's Disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 19, 109-116.